CuraSen Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.curasen.com
Clinical Trials
10
Active:2
Completed:2
Trial Phases
3 Phases
Phase 1:5
Phase 2:3
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 2
3 (33.3%)Not Applicable
1 (11.1%)A Study in Subjects With Neurogenic Orthostatic Hypotension
Not Applicable
Not yet recruiting
- Conditions
- Neurogenic Orthostatic Hypotension
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- CuraSen Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT07089043
- Locations
- 🇺🇸
CuraSen Investigational Site, Nashville, Tennessee, United States
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease
Phase 2
Completed
- Conditions
- Mild Cognitive ImpairmentDementia
- Interventions
- Drug: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- CuraSen Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05104463
- Locations
- 🇳🇿
CuraSen Investigational Site, Christchurch, New Zealand
A Study of CST-2032 in Subjects With Cognitive Impairment
Phase 1
Withdrawn
- Conditions
- Mild Cognitive Impairment (MCI)Parkinson Disease (PD)
- Interventions
- Drug: CST-2032, matching placebo for CST-2032, CST-107
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- CuraSen Therapeutics, Inc.
- Registration Number
- NCT05033912
A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)
Phase 2
Withdrawn
- Conditions
- Freezing of Gait Symptoms in Parkinson's Disease
- Interventions
- Drug: CST-103, CST-107, matching placebo
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- CuraSen Therapeutics, Inc.
- Registration Number
- NCT04935762
- Locations
- 🇦🇺
The University of Sydney, Sydney, New South Wales, Australia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
Phase 2
Completed
- Conditions
- Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- CuraSen Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04739423
- Locations
- 🇦🇺
The University of Sydney, Sydney, New South Wales, Australia
🇦🇺Wesley Medical Research Ltd, Brisbane, Queensland, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
News
No news found